Communicated by: Shinichi Aizawa
Differentiation of mouse and human embryonic stem cells into hepatic lineages
Version of Record online: 30 MAY 2008
© 2008 The Authors. Journal compilation © 2008 by the Molecular Biology Society of Japan/Blackwell Publishing Ltd
Genes to Cells
Volume 13, Issue 7, pages 731–746, July 2008
How to Cite
Shiraki, N., Umeda, K., Sakashita, N., Takeya, M., Kume, K. and Kume, S. (2008), Differentiation of mouse and human embryonic stem cells into hepatic lineages. Genes to Cells, 13: 731–746. doi: 10.1111/j.1365-2443.2008.01201.x
- Issue online: 4 JUL 2008
- Version of Record online: 30 MAY 2008
- Received: 4 February 2008Accepted: 10 April 2008
- Top of page
- Experimental procedure
- Supporting Information
We recently reported a novel method to induce embryonic stem (ES) cells differentiate into an endodermal fate, especially pancreatic, using a supporting cell line. Here we describe the modified culture condition with the addition and withdrawal of secreted growth factors could induce ES cells to selectively differentiate into a hepatic fate efficiently. The signaling of BMP and FGF that have been implicated in hepatic differentiation during normal embryonic development are shown to play pivotal roles in generating hepatic cells from the definitive endoderm derived from ES cells. Moreover, the expression of AFP, Albumin or a biliary molecular marker appeared sequentially thus suggested the differentiation of ES cells recapitulated normal developmental processes of liver. The ES cell-derived differentiated cells showed evidence of glycogen storage, secreted Albumin, exhibited drug metabolism activities and expressed a set of cytochrome or drug conjugate enzymes, drug transporters specifically expressed in mature hepatocytes. With the same procedure, human ES cells also gave rise to cells with mature hepatocytes’ characteristics. In conclusion, this novel procedure for hepatic differentiation will be useful for elucidation of molecular mechanisms of hepatic fate decision at gut regionalization, and could represent an attractive approach for a surrogate cell source for pharmaceutical studies such as toxicology.
- Top of page
- Experimental procedure
- Supporting Information
Liver performs many complex functions including carbohydrate metabolism, urea and lipid metabolism, storage of essential nutrients, production and secretion of bile acids, into which metabolites of drugs and other compounds are excreted. Hepatic biotransformation of a drug involves activations of inactive prodrugs to active drugs, inactivations, detoxifications as well as adverse activations, where some metabolites are more toxic than the parent drug molecules. Thus, examination of drug biotransformation using human liver cells plays an important role in the early stages of the drug discovery process. However, primary liver cells are short-lived and cannot be maintained in culture for long term. Considerable donor dependent variations are also problematic. Embryonic stem (ES) cells are pluripotent cells derived from the inner cell mass of the blastocysts. They apparently differentiate into various types of mature cells, thereby are attractive source for routine access to large numbers of cells that can be used for the development of new drug-screening strategies instead of primary cells (Davila et al. 2004; Kulkarni & Khanna 2006).
The vertebrate liver develops from the ventral foregut endoderm (Wells & Melton 1999; Zaret 2000). Although several lines of evidences have shown that different regions of the gut are patterned by signals from the underlying mesoderm, the mechanism of how specific endoderm tissues differentiate remains much unknown. In hepatic development, fibroblast growth factors (FGF) and bone morphogenetic proteins (BMP) originated from the cardiac mesoderm and the septum transversum mesenchyme are shown to be essential for cardiac induction, promotion of liver gene expression and endoderm proliferation (Jung et al. 1999; Rossi et al. 2001). FGF signaling from the cardiac mesoderm directs the overlying ventral endoderm to use a hepatic fate instead of a pancreatic fate (Deutsch et al. 2001).
Several studies reported the induction of ES cell differentiation into hepatic cells both in vitro and in vivo. The in vitro approaches involve the formation of embryoid bodies to mimic the inductive microenvironment required for liver organogenesis (Asahina et al. 2004; Heo et al. 2006) or treatment with specific growth factors and cytokines critical for hepatocyte differentiation (Teratani et al. 2005). Also the co-cultivation of ES cells with embryonic mesenchymal cells was shown to direct ES cells toward a hepatic lineage (Ishii et al. 2005; Saito et al. 2006; Soto-Gutierrez et al. 2006). Recently, in vitro generation of ES cell-derived hepatic cells was reported by using BMP4 (Gouon-Evans et al. 2006). Although these findings are encouraging, there are few studies for fate divergence from gut endoderm into liver, pancreas and intestine cells. Hepatic differentiation of ES cells in most studies was not efficient for producing enough amounts of functional mature hepatocytes.
We have established a novel procedure to direct ES cells differentiate into regional specific gut endoderm lineages, such as liver, pancreas, lung or intestine, by co-cultivation with a supporting mesoderm-derived cell line, M15, with selective culture conditions. Using this novel procedure, the present study documents an efficient induction of ES cells into morphologically, and biologically functional hepatocytes. Moreover, this method was applicable to human ES cells. Under selective culture conditions, approximately 80% of the human ES cells can be manipulated to differentiate into α-fetoprotein (AFP)-positive cells, and 9% of total cells turned to Albumin-positive cells. Analysis of the hepatic cells derived from ES cells showed that these cells resemble mature hepatocytes in that they store glycogen, and expressed various molecular markers such as Albumin, bile acid transporters and cytochrome P450 metabolic enzymes.
- Top of page
- Experimental procedure
- Supporting Information
M15, a mesoderm-derived cell line, directs ES cells to differentiate into endodermal and hepatic lineages
We have recently established a co-cultivation method using a mesoderm-derived cell line, M15. ES cells grown on M15 and treated with activin and bFGF during the first 4 days of differentiation, are sequentially directed to differentiate into mesendoderm and then into definitive endoderm. A prolonged addition of activin and bFGF on d4–d8 (days 4–8) specifically increased pancreatic differentiation marked by an increase in pancreatic and duodenal homeobox gene 1 (Pdx1)-expressing cells, whereas the withdrawal of activin and bFGF induced Afp expression (Shiraki et al. 2008).
In an attempt to find a condition in which ES cells dominantly adopt a hepatic fate instead of a pancreatic fate, activin and bFGF were added to ES cells grown on M15 on d0–d4, and then withdrawn. On d4–d8, various soluble factors were examined, in combination with media supplemented with FBS or KSR, with varied glucose concentrations (2000 mg/L or 4500 mg/L). Hepatocyte growth factor (HGF), oncostatin M (OsM) or dexamethasone (Dex) were included because these were reported to potentiate hepatic differentiation of ES cells (Michalopoulos et al. 2003; Teratani et al. 2005).
On d8, both definitive endoderm and pancreatic cells were quantified by flow cytometry using E-cadherin+/Cxcr4+ (Yasunaga et al. 2005) and Pdx1 as markers, respectively. To quantify Pdx1 expression, we used an ES cell line, SK7, established from a transgenic mouse line P#48.9 (Gu et al. 2004) bearing a Green fluorescent protein (GFP) reporter driven by the promoter for Pdx1 (Shiraki et al. 2008). Figure 1A shows that the proportion of both the E-cadherin+/Cxcr4+ cells and GFP+ (Pdx1-expressing) cells increased when activin and bFGF were added on d4–d8 (Fig. 1A, filled bars). The addition of Dex, HGF and OsM decreased the proportion of E-cadherin+/Cxcr4+ cells as well as Pdx1-expressing cells (Fig. 1A).
To define the extent of hepatic differentiation within gut definitive endoderm, we quantified transcript levels for Afp, an early hepatic marker (Shiojiri 1981), and Sonic hedgehog (Shh), which is expressed in the foregut region but excluded in the pancreatic and hepatic buds (Burke & Oliver 2002) (Fig. 1B). Afp was induced under KSR, but not FBS condition. Moreover, under low glucose condition, and with the presence of Dex, HGF and OsM, the definitive endoderm cells turned out to give a maximum expression of Afp (gray bar in 2000KSR). When activin and bFGF are added, a pancreatic fate is favored, shown by an increase in Pdx1/GFP positive cells (Fig. 1A, black bars), and a decrease in Shh and Afp transcripts (Fig. 1B, black bars). Conversely, when Dex, HGF and OsM were added, a non-pancreatic fate is favored (Fig. 1A,B, gray bars).
Immunocytochemistry (ICC) further confirmed that culture conditions for the generation of Pdx1- and AFP-expressing cells are mutually complementary and most of them arose from distinct colonies (Fig. 2A). Continuous addition of activin and FGF yielded Pdx1-expressing cells dominantly (activin and bFGF columns). Withdrawal of these factors followed by the addition of Dex, HGF and OsM in medium supplemented with a lower glucose concentration of 2000 mg/L and KSR instead of FBS yielded a substantial number of AFP expressing cells in the expense of Pdx1-expressing cells (2000KSR, Dex and HGF and OsM). The present result that hepatic differentiation is enhanced under serum free condition agrees well with previous reports (Kubo et al. 2004; Heo et al. 2006).
Either the single or the combinatory additions of Dex, HGF and OsM were examined with medium supplemented with KSR and lower glucose (2000 mg/L). Figure 2B shows that the effects of promoting AFP expression are in an order of Dex > HGF > OsM. Addition of Dex and HGF was enough to result in a maximum potentiation of ES cell differentiation into AFP-expressing cells.
Thus, for maximum definitive endoderm differentiation, the following procedure was adopted: ES cells are cultured for 4 days (d0–d4) in a medium with activin, bFGF, FBS and high glucose (4500 mg/L), then the medium is switched to that with KSR, low glucose (2000 mg/L), and various growth factors and their inhibitors of interest.
BMP and FGF signals are pivotal for hepatic differentiation of the definitive endoderm from ES cells
As it is reported that BMP and FGF signaling are involved in hepatic differentiation (Jung et al. 1999; Rossi et al. 2001), their effects on definitive endoderm cells were tested (Fig. 2C,D). Addition of bFGF increased AFP-positive cells, whereas addition of SU5402, a specific inhibitor of FGF receptor I, decreased AFP-positive cells. Noggin addition abolished most of the AFP-expressing cells, which was recovered by bFGF addition (Fig. 2C,D). These results show that BMP signaling is required in the induction of hepatocyte differentiation, whereas FGF signaling potentiates BMP signal.
Chronological analysis showed a sequential induction of molecular markers demonstrating the differentiation of hepatoblasts and hepatocytes, and cells of the bile duct cell lineages.
The cultures were then extended up to d30 and the chronological expressions of hepatic molecular markers were studied. Figure 3A shows that AFP single positive cells first appeared, and then Albumin-positive cells are detected on d18. On d18, there are cells expressing both AFP and Albumin. Later on, the proportion of AFP-expressing cells decreased, and Albumin-expressing cells increased. On d8 and d30, the proportions of AFP-positive cells were 33.1% and 7.4%, respectively (Supplementary Table S2). The results that AFP and Albumin are differentially regulated suggest that the ES cells differentiate to immature hepatic precursors (AFP+/Albumin–), then hepatoblast (AFP+/Albumin+) and then hepatocyte (AFP–/Albumin+), which appears to be coincident with the development of hepatic lineages in mouse embryos (Shiojiri 1981, 1984).
As the hepatoblasts are bipotential progenitors capable to differentiate into hepatocyte and bile duct lineages, we then assayed for the generation of bile duct lineage in the culture. ICC analysis on d30 showed that cells of the hepatocyte lineage and bile duct lineage segregated and formed distinct colonies of Albumin+ (17.8%) or Dolichos biflorus agglutinin (DBA)+ (72.9%) (Takahashi et al. 1995) (Fig. 3B, Supplementary Table S2).
At the same time, ICC analysis of mature molecular markers showed that some of the Albumin-positive cells expressed mature hepatic markers such as α-1-antitrypsin, and two members of the cytochrome P450 (Cyp) enzymes Cyp3A or Cyp7A1 (Fig. 3C). α1-Antitrypsin (Travis & Salvesen 1983; Potempa et al. 1994) is a serine protease and trypsin inhibitor, Cyp3A is a member of the cytochrome P450 subfamilies involved in drug and steroid metabolism (Wrighton & Stevens 1992), Cyp7A1 is a cholesterol 7 α-hydroxylase and regulates the pathway through which cholesterol is converted into bile acids. Cyp7A1 is expressed in the liver and not in the yolk sac tissue, and thus serves as a good marker for hepatocytes (Asahina et al. 2004).
Functional characterization of the ES cell-derived hepatic cells
To define the extent of maturation of the hepatic cells, real-time PCR analysis of hepatic molecular markers were carried out on d10 and d30 differentiated ES cells (Fig. 4). The expression levels of the molecular markers were compared with those in E12.5 fetal liver or adult liver. At E12.5, fetal liver also acts as hematopoietic tissue and is rich in hematopoietic cells. CD45–/Ter199– (double negative) E12.5 fetal liver cells were recovered and subjected to real-time PCR analysis (Fig. 4, FL). Afp transcripts decreased at d30, which agrees well with the above ICC data (Fig. 3, Supplementary Table S2). Transcripts of Alb1, Keratin 7 (Cytokeratin 7; Krt 7), Keratin 19 (Cytokeratin 19; Krt19), or mature markers of cytochrome P450 enzyme Cyp7a1, Cyp2b10, Cyp3a11, Cyp3a13, hydroxysteroid sulfotransferase (Sult2a1), UDP-glucuronosyltransferase (Ugt1a1), organic anion transporting polypeptides (Slco1a4) or bile salt export pump (Abcb11) (Choudhary et al. 2003; Wagner et al. 2005) were also examined (Fig. 4). These mature hepatocyte markers were detectable at d10, which increased to a substantial level at d30 of differentiation. Most of the expression levels of the markers were similar to those of the fetal liver. Ugt1a1, Cyp7a1, Cyp2b10, Cyp3a13 and Slco1a4 expressions were higher than those of fetal liver, but lower than those of adult liver. These results thereby show that the ES cell-derived differentiated cells expressed many of the mature hepatocyte markers.
Next we carried out functional studies to characterize the ES cell-derived hepatic cells. In mouse embryo, a small proportion of hepatocytes begin to accumulate glycogen in the cytoplasm from E15.5, and then hepatocytes rich in glycogen increased in number in the liver of E16.5 and E17.5 (Shiojiri 1981). Most cells on d30 of differentiation were positive for periodic acid Schiff (PAS) staining indicative of glycogen storage, a characteristic of mature hepatocytes (Fig. 5A, d30).
Because OsM is reported to induce maturation of mouse fetal hepatocytes (Kamiya et al. 2001, 2002), the effect of OsM on Albumin secretion was assayed with an ELISA. Figure 5B showed that the Albumin secretion was not detected at d8 when hepatoblast-like (AFP+/Albumin+) cells appeared (Fig. 3). The potentiation effect of OsM on Albumin secretion was not observed until d40 of differentiation. At d50 and d60, a twofold increase in Albumin secretion was detected in OsM, Dex and HGF supplemented differentiation media compared to control media supplemented with Dex and HGF.
Cyp3A4 is known to be involved in the metabolism of more than half of all currently used drugs. Several well-documented cases exhibiting clinically important drug–drug interactions and toxicities are implicated to be related to Cyp3A4 inhibition. Cyp3a11 and Cyp3a13, two important Cyp3A isoforms identified in the mouse, are expressed in differentiated ES cells (Fig. 4). Cytochrome P450 3A activity of ES cells differentiated for 60 days was tested (Fig. 5C). ES cell-derived hepatic cells (d60) exhibited metabolic activities approximately one-fifth of that of adult liver. These data are consistent with real-time PCR results (Fig. 4).
Application to human ES cells
To test if the present culture procedure could be applied to human ES cells, KhES-1 cells were treated at d0–d10 with activin and LY294002, a potent PI3 kinase inhibitor, which was shown to efficiently promote endoderm differentiation from undifferentiated ES cells (McLean et al. 2007). As there is evidence for a role of the FGF singling pathway in maintaining pluripotency of human ES cells (Amit et al. 2000), bFGF was not used in the present procedure for differentiation of human ES cells although it promoted endoderm differentiation in mouse ES cells.
Figure 6A shows the expression levels of the transcripts of endoderm or hepatic markers in human ES cell-derived differentiated cells (d18, d30). An endoderm marker, Sox17 as well as Afp, Alb, Cytokeratin 7 (CK7), Cytokeratin 18 (CK18), Cytokeratin 19 (CK19) and Cyp7a1 were detected in differentiated ES cells on d18. On d30, the expression of Afp decreased, along with a marked increase in Alb expression. ICC analyses show that AFP is induced in approximately 40% of total cells on d14 (Fig. 6B, Supplementary Table S2). Addition of Dex, HGF at d10 and thereafter increased the proportion of AFP-expressing cells with concomitant decrease in Oct3/4 expressing undifferentiated ES cells (Supplementary Table S2). Albumin positive cells are detected on d18, where there are cells expressing both AFP and Albumin (Fig. 6B). The proportion of AFP-expressing cells decreased much more slowly comparing with mouse ES cells (Supplementary Table S2). On d30, colonies of Albumin single positive cells, which did not express AFP, become evident (Fig. 6B). On d20, approximately 80% of the human ES cells differentiated into AFP-positive cells, and on d40, 9% of total cells were Albumin-positive hepatocytes. These results suggest that the human ES cell-derived hepatic cells differentiate sequentially to form hepatocyte precursor, hepatoblast, and then hepatocyte or bile duct lineages similarly with that observed in mouse ES cells, but there were differences in the length of time window required for the process of maturation.
Next, to examine the extent of maturation of the human ES cell-derived hepatic cells, hepatic molecular markers were analyzed by quantitative PCR with d18 and d50 cultures (Fig. 7A). The expression levels of the molecular markers were compared with those in 22–40 weeks old fetal liver or adult liver. Afp was expressed on d18, and decreased on d50. The expression level on d50 was much higher than that of fetal liver. The mature hepatocyte markers such as Albumin (Alb), Cyp3a4, liver-specific organic anion transporting polypeptides 1B1 (Oatp1b1) (Hsiang et al. 1999; Konig et al. 2000) were detected on d18 and increased to a substantial level on d50 (Fig. 7A). Most cells on d24 and d50 were PAS-positive, demonstrating glycogen deposition (Fig. 7B).
Ultrastructures of the differentiated human ES cells grown for 50 days were evaluated by electron microscopy (Fig. 7C–E). ES cell-derived cells were rich in organella such as mitochondria (Mt), endosome (En), lysosome (Ly), rough ER (rER), Golgi apparatus (Go), being consistent with typical hepatocytes with active protein synthesis (Fig. 7C–E). In addition, some of the cells formed biliary canaliculi (Bc) with microvilli associated with intracellular filament (Fi) and cell junctional complexes (arrows) (Fig. 7C). Consistent with results from PAS staining, most of ES cell-derived cells were rich in glycogen granules (g), and convoluted forms of smooth endoplasmic reticulums (sER) were also found in the cytoplasm (Fig. 7D). Furthermore, some of these cells showed characteristic epithelial like structure with polarization (Fig. 7E); well-developed microvilli were prominent on the one side of the cell surface (Fig. 7E, arrowhead), and cell junction complex also observed on the lateral side (Fig. 7E, arrow). These results indicate that ES cell-derived hepatic cells show normal hepatocyte ultrastructure.
- Top of page
- Experimental procedure
- Supporting Information
We previously reported a novel procedure for in vitro differentiation of ES cells into definitive endoderm lineages by growing ES cells on a supporting cell line, M15, and that by modification of the culture condition, the differentiation efficiency of ES cell into Pdx1-expressing cells markedly increased (Shiraki et al. 2008). The molecular mechanism for each inductive process during the entire differentiation procedure was extensively studied (Shiraki et al. 2008). With this information, we are able to optimize the condition for selective induction of hepatic fate versus a pancreatic fate of the definitive endoderm at a high efficiency (Fig. 1). Several groups have recently reported the differentiation of ES cells into hepatic cells (Gouon-Evans et al. 2006; Soto-Gutierrez et al. 2006; Cai et al. 2007). However, this is the first report demonstrating the expression of mature hepatocytes markers of various transporters and metabolizing enzymes, such as Sult2a1, Ugt1a1, Cyp7a1, Cyp2b10, Cyp3a11, Cyp3a13, Slco1a4, Abcb11 (Fig. 4). Moreover, under present culture condition, the mature hepatocytes can be maintained over 60 days in vitro (Fig. 5).
During mouse development, the induction of hepatic genes occurs approximately E8.5 (Lemaigre & Zaret 2004), and it requires FGF signaling from adjacent cardiac mesoderm (Jung et al. 1999) and BMP2 and 4 from the septum transversum mesenchyme cells (Rossi et al. 2001). Then the endoderm starts to bud out into the stromal environment, where they interact with endothelial cells (Matsumoto et al. 2001). When the hepatic endoderm is specified, they are referred to as hepatoblasts (Lemaigre & Zaret 2004). The bipotential hepatoblasts are capable of differentiating into hepatocytes or bile duct cells. Our results suggest that hepatic differentiation is enhanced under serum free condition which agrees with previous reports (Kubo et al. 2004; Heo et al. 2006) that serum inhibits hepatic differentiation. It is also showed that removal of serum strongly enhanced hepatic induction while inhibiting Pdx1 expression, indicating that there were unknown serum factors inhibiting hepatic differentiation (Figs 1, 2). We found that the treatment of Dex, HGF and OsM under serum containing conditions increased the expression level of Shh, but not Afp in mouse ES cells (Fig. 1B). Shh is expressed in the foregut but not pancreatic or hepatic epithelia. Thus these results suggested that endoderm-derived cells other than pancreas and liver were differentiated under the above culture condition. Taken together, our differentiation systems using M15 provide a good tool for investigation of regionalization of gut endoderm in vitro.
We also examined the effects of BMP, bFGF and their antagonists, Noggin or SU5402 (Fig. 2A,B). Although bFGF increased AFP-expressing cells, SU5402 decreased. Noggin completely abolished AFP-expressing cells, and this was rescued by bFGF, demonstrating that BMP4 and bFGF are both required for hepatic differentiation. The addition of BMP did not show potentiation effects on the formation of AFP positive cells in this study (Fig. 2C,D). We speculated that endogenous BMP secretion from M15 cells, in which Bmp4 is highly expressed (Shiraki et al. 2008), is sufficient. The above results agree with a recent report that in vitro generation of ES cell-derived hepatic cells requires BMP4 (Gouon-Evans et al. 2006), and are consistent with previous reports using mouse embryo (Jung et al. 1999; Rossi et al. 2001), thereby suggesting that in vitro hepatic differentiation using our method recapitulates the mouse hepatic development.
HGF has been reported as a regulator of hepatoblast bipotency (Suzuki et al. 2002, 2003). Dex is a synthetic glucocorticoid hormone active in induction of enzymes concerned in gluconeogenesis in the liver (McGrane et al. 1990; Michalopoulos et al. 2003). In our present studies, HGF and Dex promoted expression of AFP and Albumin (Fig. 2). Afp transcription was reported to start soon after fertilization, whereas the Alb1 transcripts was detected by RT-PCR, at the earliest, on E13.5 (Petkov et al. 2004). Our present results show a temporally correlated expression pattern of Afp and Alb (Fig. 3) thereby indicating recapitulation of normal liver embryonic developmental program. DBA lectin-positive bile duct cells were also generated from ES cells, indicating that the present procedure could induce cells of the hepatic lineages, including bile duct cells and hepatocytes (Fig. 3). Enzymes function in the detoxification pathway; such as Sult2A, Ugt1A, Cyp2b10, Cyp3a11 and Cyp3a13, are induced (Fig. 4). Biochemical analyses indicated that ES cell-derived hepatocytes deposited glycogen, which are characteristics of normal mature hepatocytes (Fig. 5A).
However, most of the genes expressed in the hepatic cells are also expressed in the extra embryonic yolk sac tissue. AFP and Albumin, which are widely used as hepatic marker, are also expressed in both tissues. In order to discriminate between these two populations of cells, ICC of Cyp7a1, a hepatocyte specific marker which is not expressed in the extra-embryonic yolk sac tissue, was carried out. As shown in Figs 3C and 6A, both mouse and human ES cell-derived differentiated cells expressed Cyp7A1, thereby suggesting that Albumin-positive cells derived from ES cells are hepatic cells but not extra embryonic cells.
Maturation of the liver is reported to be governed by cytokine signaling (Matsumoto et al. 1994; Kinoshita & Miyajima 2002). Studies using hepatoblast culture system have shown that OsM, which is secreted from hematopoietic cells within the fetal liver, contributes to control late stages of hepatocyte differentiation (Kamiya et al. 1999; Kamiya & Gonzalez 2004). Albumin secretion assay suggests that OsM promotes hepatic maturation in our differentiation systems (Fig. 5B). Finally ES cell-derived hepatic cells grown with Dex, HGF and OsM for 60 days exhibit some extents of drug metabolism activity (Fig. 5C).
A human ES cell line, KhES-1 (Suemori et al. 2006), was also subjected to the similar procedure as mouse ES cells and cultured on M15 cells as a supporting cell. KhES-1 gave rise to abundant AFP-positive cells, and by combination of growth factors, they expressed AFP and Albumin in a sequential way similar to that of mouse ES cells. This suggests that KhES-1 cells adopt similar pathway toward hepatocytes (Fig. 6A,B). Additionally, the results of PAS staining, quantitative PCR analysis and transmission electron microscopy suggest that human ES cell-derived cells have the characteristics of mature hepatocytes (Fig. 7).
In conclusion, the use of M15 as supporting cells for the differentiation of ES cells has been proven to be a powerful tool for regulating ES cell differentiation especially into endodermal fate. The differentiation process recapitulates normal development, thus helps understanding the molecular mechanism of the processes of induced differentiation of cells of the endoderm lineages. The applicability of this method to human ES cells would yield the potential tools for drug discovery or regenerative medicine in the future.
- Top of page
- Experimental procedure
- Supporting Information
ES cell lines
The mouse ES cell line, SK7, containing a Pdx1 promoter-driven GFP reporter transgene, was established by culturing blastocysts obtained from transgenic mice homozygous for the Pdx1/GFP gene (Shiraki et al. 2008). The SK7 ES cell line was maintained on mouse embryonic fibroblast (MEF) feeders in Glasgow minimum essential medium (Invitrogen, Glasgow, UK) supplemented with 1000 units/mL leukemia inhibitory factor (LIF; Chemicon, Temecula, CA), 15% Knocked-out Serum Replacement (KSR; Gibco, Funakoshi, Tokyo, Japan), 1% fetal bovine serum (FBS; Hyclone, Logan, UT), 100 µm non-essential amino acids (NEAA; Invitrogen, Carlsbad, CA), 2 mm l-glutamine (l-Glu; Invitrogen), 1 mm sodium pyruvate (Invitrogen), 50 units/mL penicillin and 50 µg/mL streptomycin (PS; Invitrogen) and 100 µmβ-mercaptoethanol (β-ME; Sigma, St Louis, MO). The human ES cells (KhES-1) (Suemori et al. 2006) were a gift from Dr N. Nakatsuji and Dr H. Suemori (Kyoto University, Kyoto, Japan) and were used after the hES cell guidelines of the Japanese government. Undifferentiated hES cells were maintained on a feeder layer of MEF in DMEM/F12 (Sigma) supplemented with 20% KSR, l-Glu, NEAA and β-ME under 3% CO2. To passage hES cells, hES cell colonies were detached from the feeder layer by treating them with 0.25% trypsin and 0.1 mg/mL collagenase IV in PBS containing 20% KSR and 1 mm CaCl2 at 37 °C for 5 min, followed by adding culture medium and disaggregating ES cell clumps into smaller pieces (5–20 cells) by gentle pipetting several times.
The mesonephric cell line M15, which expresses WT1, was established from mouse mesonephros over-expressed with the large T protein of polyoma virus under the control of the early viral enhancer. M15 cells (Larsson et al. 1995) was kindly provided by Dr T. Noce (Mitsubishi Kagaku Institute of Life Science, Tokyo, Japan) and Dr M. Rassoulzadegan (University of Nice-Sophia Antipolis, Antipolis, France). M15 cells (Larsson et al. 1995) were grown in DMEM supplemented with 10% FBS. M15 cells were treated with mitomycin C at 10 µg/mL for 2.5 h before use. M15 were seeded on gelatin-coated 6-well or 24-well plates at a concentration of 8 × 105 cells or 2 × 105 cells per well, respectively.
Growth factors and inhibitors
Reagents were purchased and used at the designated concentrations as follows; recombinant human activin-A (R&D Systems, Minneapolis, MN), 20 ng/mL; recombinant human bFGF (Peprotech, London, UK), 50 ng/mL; recombinant human BMP4 (R&D Systems), 50 ng/mL; LY294002 (Calbiochem, San Diego, CA), 10 µm; SU5402 (Calbiochem), 10 µm; recombinant mouse Noggin/Fc Chimera (R&D Systems), 100 ng/mL; recombinant human Hepatocyte Growth Factor (HGF, Peprotech), 10 ng/mL; Dexamethasone (Dex, Sigma), 1 µm; recombinant human Oncostatin M (OsM, Sigma).
Differentiation of ES cells
For differentiation studies, ES cells were plated at 5000 or 20 000 cells per well in 24-well or 6-well plates (Nunc), respectively, that had been previously coated with M15 cells. The cells were cultured in differentiation medium supplemented with 10% FBS and 4500 mg/L glucose on d0–d4, and were switched to 10% KSR and 2000 mg/L glucose at d4 and on, in DMEM with NEAA, l-Glu, PS and β-ME for up to 60 days. Activin A (20 ng/mL) and bFGF (50 ng/mL) were added on d0–d4 of differentiation (Shiraki et al. 2008), withdrawn and switched to as noted in the text on d4 and on. Media were replaced every 2 days with fresh medium supplemented with growth factors.
In the case of human ES cells, KhES-1 cells were plated at 20 000 or 80 000 cells per well in 24-well or 6-well plates, respectively, that had been plated with M15 cells. ES cells were cultured in differentiation medium (DMEM supplemented with 10% KSR, 4500 mg/L glucose, NEAA, l-Glu, PS and β-ME) for up to 50 days. Activin A (20 ng/mL) and LY294002 (10 µm) were added on d0–d10 of differentiation, HGF (10 ng/mL) and Dex (1 µm) were added on d10–d50. Media were replaced every 2 days with fresh differentiation medium supplemented with growth factors.
Flow cytometry analysis
Either of the following antibodies were used: biotin-conjugated anti-E-cadherin monoclonal antibody (mAb) ECCD2 (Shirayoshi et al. 1986), biotin-conjugated anti-CD45 mAb B220 (eBioscience, San Diego, CA), biotin-conjugated anti-TER-119 mAb (eBioscience) or phycoerythrin (PE)-conjugated anti-Cxcr4 mAb 2B11 (BD Biosciences Pharmingen, San Diego, CA). The stained cells were analyzed with a FACS Canto (BD) or purified with FACS Aria (BD). Data were recorded with the BD FACS Diva Software program (BD) and analyzed using the Flowjo program (Tree Star, San Carlos, CA).
RNA was extracted from ES cells or mouse liver using RNeasy mini-kit (Qiagen, Hilden, Germany) and then treated with DNase (Qiagen). Human fetal (22–40 weeks old) and adult (51-years-old) liver total RNA were purchased from Clontech Laboratories, Inc., Mountain View, CA. For reverse transcription reactions, 3 µg RNA was reverse-transcribed using MMLV reverse transcriptase (Toyobo, Osaka, Japan) and oligo dT primers (Toyobo). One microliter of fivefold diluted cDNA (1% of the RT product) was used for PCR analyses. The primer sequences for each primer set are shown in Supplementary Table S1 in the supplementary material. For real-time PCR analysis, the mRNA expression was quantified with SyberGreen on an ABI 7500 thermal cycler (Applied Biosystems, Foster City, CA). The level of each gene expression was normalized with that of β-actin. The PCR conditions were as follows: denaturation at 95 °C for 15 s, annealing and extention at 60 °C for 60 s, for up to 40 cycles. Each measurement were normalized to β-actin (mouse) and Gapdh (human) for each sample by subtracting the average β-actin (mouse) and Gapdh (human) Ct values (Threshold Cycle) from the average Each gene Ct, resulting in Ct. Each target mRNA levels, expressed as arbitrary units, were determined by standard curve method.
For whole-mount ICC, ES cells were plated on 24-well Thermanox cover slips (Nunc). Confocal images were obtained using a TCS-SP2 Spectral Confocal Scanning System (Leica). Phase contrast images were obtained using IX71 Inverted Microscope (Olympus). The following antibodies were used to detect: mouse anti-GFP (Roche, Basel, Switzerland), rabbit anti-α-fetoprotein (AFP, Biomeda, Foster City, CA), goat anti-Albumin (Sigma), fluorescein isothiocyanate (FITC)-conjugated Dolichos biflorus agglutinin (DBA) lectin (Sigma), rabbit anti-α-1-antitrypsin (Sigma), rabbit anti-CYP3A2 (Biomol, Plymouth Meeting, PA), rabbit anti-CYP7A1 (Santa Cruz, Santa Cruz, CA), mouse anti-Oct3/4 (Santa Cruz) Secondary antibodies used were Alexa 568-conjugated goat anti-rabbit, donkey anti-goat antibodies (Molecular Probes, Eugene, OR); Alexa 488-conjugated goat anti-mouse and anti-rabbit, donkey anti-goat antibodies (Molecular Probes). Cells were counterstained with DAPI (Roche). The numbers of stained cells in Fig. 3 were quantified by analyzing, the areas of AFP-positive staining images using Lumina Vision program (Mitani Corporation, Chiba, Japan) (Supplementary Table S2).
Periodic acid Schiff analysis
The cultured cells were fixed in 3.3% formalin for 10 min, and intracellular glycogen was stained using a PAS staining solution (Muto Pure Chemicals, Tokyo, Japan), according to the manufacturer's instructions.
Albumin secretion assay
The culture media were replaced with fresh media and the conditioned media were harvested 24 h later and were assayed for Albumin secretion using the Lebis ELISA kit (Shibayagi, Gunma, Japan).
Assay for cytochrome P450 3A activity
To confirm cytochrome P450 3A activity, 3 µg samples of microsomes were analyzed using the P450-GloTM CYP3A4 Assay Kit (Promega, Madison, WI). Microsomes were prepared from livers of 6-week-old male ICR mice, undifferentiated ES cells, and differentiated ES cells. The protein content of the microsome preparations was measured using the Micro BCATM Protein Assay Kits (Pierce, Rockford, IL).
Transmission electron microscopy
Human ES cell-derived hepatic cells grown on M15 in tissue culture plates for 50 days were fixed with 2% glutaldehyde–cacodylate buffer for 30 min, post-fixed with 1% osmium tetroxide for 30 min, after which they were dehydrated with graded series of ethanol. Samples were embedded in Epok 812 (Oken Trading, Tokyo, Japan), and ultrathin sections were cut with an ultramicrotome (MT7000-Ultra; RMC, Tucson, AZ). Samples were stained with uranyl acetate and lead citrate and were then viewed with an electron microscope (H-7500; Hitachi, Tokyo, Japan).
- Top of page
- Experimental procedure
- Supporting Information
We thank Drs Norio Nakatsuji and Hirofumi Suemori (Kyoto University) for providing KhES-1 cells. We thank members of Gene Technology Center for technical assistance. This work was supported by grants (No. 17045026 to S.K.), from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), by a grant (to S.K.) from the Project for Realization of Regenerative Medicine from MEXT, and from the New Energy and Industrial Technology Development Organization (NEDO), and in part a global Century Center-of-Excellence grant (G.COE) grant (Cell Fate Regulation Research and Education Unit) from MEXT, Japan. N.S. is a research associate of IMEG. S.K. is a member of G.COE Program.
- Top of page
- Experimental procedure
- Supporting Information
- 2000) Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev. Biol. 227, 271–278. , , , , , , & (
- 2004) Expression of the liver-specific gene Cyp7a1 reveals hepatic differentiation in embryoid bodies derived from mouse embryonic stem cells. Genes Cells 9, 1297–1308. , , , , , , , & (
- 2002) Prox1 is an early specific marker for the developing liver and pancreas in the mammalian foregut endoderm. Mech. Dev. 118, 147–155. & (
- 2007) Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology 45, 1229–1239. , , , , , , , , , , , & (
- 2003) Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch. Biochem. Biophys. 414, 91–100. , , , & (
- 2004) Use and application of stem cells in toxicology. Toxicol. Sci. 79, 214–223. , , , , & (
- 2001) A bipotential precursor population for pancreas and liver within the embryonic endoderm. Development 128, 871–881. , , , & (
- 2006) BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm. Nat. Biotechnol. 24, 1402–1411. , , , , , , & (
- 2004) Global expression analysis of gene regulatory pathways during endocrine pancreatic development. Development 131, 165–179. , , , , & (
- 2006) Hepatic precursors derived from murine embryonic stem cells contribute to regeneration of injured liver. Hepatology 44, 1478–1486. , , , , , , & (
- 1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl–CoA reductase inhibitor transporters. J. Biol. Chem. 274, 37161–37168. , , , , , & (
- 2005) In vitro differentiation and maturation of mouse embryonic stem cells into hepatocytes. Exp. Cell Res. 309, 68–77. , , , , , , , , , & (
- 1999) Initiation of mammalian liver development from endoderm by fibroblast growth factors. Science 284, 1998–2003. , , & (
- 2004) TNF-α regulates mouse fetal hepatic maturation induced by oncostatin M and extracellular matrices. Hepatology 40, 527–536. & (
- 1999) Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer. EMBO J. 18, 2127–2136. , , , , , , , , , & (
- 2001) Oncostatin M and hepatocyte growth factor induce hepatic maturation via distinct signaling pathways. FEBS Lett. 492, 90–94. , & (
- 2002) Maturation of fetal hepatocytes in vitro by extracellular matrices and oncostatin M: induction of tryptophan oxygenase. Hepatology 35, 1351–1359. , , , & (
- 2002) Cytokine regulation of liver development. Biochim. Biophys. Acta 1592, 303–312. & (
- 2000) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G156–G164. , , & (
- 2004) Development of definitive endoderm from embryonic stem cells in culture. Development 131, 1651–1662. , , , , , , & (
- 2006) Functional hepatocyte-like cells derived from mouse embryonic stem cells: a novel in vitro hepatotoxicity model for drug screening. Toxicol. In Vitro 20, 1014–1022. & (
- 1995) Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 81, 391–401. , , , , , , , & (
- 2004) Liver development update: new embryo models, cell lineage control, and morphogenesis. Curr. Opin. Genet. Dev. 14, 582–590. & (
- 1994) Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology 20, 376–382. , , , & (
- 2001) Liver organogenesis promoted by endothelial cells prior to vascular function. Science 294, 559–563. , , & (
- 1990) Developmental regulation and tissue-specific expression of a chimaeric phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic animals. J. Reprod. Fertil. Suppl. 41, 17–23. , , , , & (
- 2007) Activin A efficiently specifies definitive endoderm from human embryonic stem cells only when phosphatidylinositol 3-kinase signaling is suppressed. Stem Cells 25, 29–38. , , , , , , , , , & (
- 2003) HGF-, EGF-, and dexamethasone-induced gene expression patterns during formation of tissue in hepatic organoid cultures. Gene Expr. 11, 55–75. , , & (
- 2004) Gene expression pattern in hepatic stem/progenitor cells during rat fetal development using complementary DNA microarrays. Hepatology 39, 617–627. , , , , , , , & (
- 1994) The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J. Biol. Chem. 269, 15957–15960. , & (
- 2001) Distinct mesodermal signals, including BMPs from the septum transversum mesenchyme, are required in combination for hepatogenesis from the endoderm. Genes Dev. 15, 1998–2009. , , & (
- 2006) Promoted differentiation of cynomolgus monkey ES cells into hepatocyte-like cells by co-culture with mouse fetal liver-derived cells. World J. Gastroenterol. 12, 6818–6827. , , , , , , , & (
- 1981) Enzymo- and immunocytochemical analyses of the differentiation of liver cells in the prenatal mouse. J. Embryol. Exp. Morphol. 62, 139–152. (
- 1984) The origin of intrahepatic bile duct cells in the mouse. J. Embryol. Exp. Morphol. 79, 25–39. (
- 2008) Guided differentiation of ES cells into Pdx1-expressing regional specific definitive endoderm. Stem Cells 26, 874–885. , , , , , , & (
- 1986) N-linked oligosaccharides are not involved in the function of a cell–cell binding glycoprotein E-cadherin. Cell Struct. Funct. 11, 245–252. , , & (
- 2006) Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes. Nat. Biotechnol. 24, 1412–1419. , , et al . (
- 2006) Efficient establishment of human embryonic stem cell lines and long-term maintenance with stable karyotype by enzymatic bulk passage. Biochem. Biophys. Res. Commun. 345, 926–932. , , , , & (
- 2003) Role for growth factors and extracellular matrix in controlling differentiation of prospectively isolated hepatic stem cells. Development 130, 2513–2524. , , , & (
- 2002) Clonal identification and characterization of self-renewing pluripotent stem cells in the developing liver. J. Cell Biol. 156, 173–184. , , , , , & (
- 1995) Bile duct-specific lectins, Dolichos biflorus agglutinin and peanut agglutinin, as probes in mouse hepatocarcinogenesis. Lab. Invest. 73, 424–432. , , , , , , & (
- 2005) Direct hepatic fate specification from mouse embryonic stem cells. Hepatology 41, 836–846. , , , , , , , & (
- 1983) Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52, 655–709. & (
- 2005) CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42, 420–430. , , , , , , , & (
- 1999) Vertebrate endoderm development. Annu. Rev. Cell Dev. Biol. 15, 393–410. & (
- 1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22, 1–21. & (
- 2005) Induction and monitoring of definitive and visceral endoderm differentiation of mouse ES cells. Nat. Biotechnol. 23, 1542–1550. , , , , , , , , & (
- 2000) Liver specification and early morphogenesis. Mech. Dev. 92, 83–88. (
- Top of page
- Experimental procedure
- Supporting Information
Table S1 PCR primers used to detect mouse gene expressions
Table S2 Immunocytochemical analysis of protein expression in ES cell-derived hepatic cells
Please note: Blackwell Publishing are not responsible for the content or functionality of any supplementary materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.
|GTC_1201_sm_TableS1.doc||25K||Supporting info item|
|GTC_1201_sm_TableS2.doc||30K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.